Tiotropium in Combination with
TO THE EDITOR: Aaron and colleagues (1) present a study designed to answer a clinically relevant question of whether 2 expensive therapies are better than 1 when the individual components seem to be separately efficacious. Unfortunately, the authors failed to consider the extent to which clinical practice had already outstripped the evidence. They report that as many as 63.6% of tiotropium-placebo recipients (the control group) were taking long-acting ␤-agonists (LABAs), usually in combination with inhaled corticosteroids at the time of enrollment, and perhaps 25% more were taking inhaled corticosteroids without LABAs. In an important sense, this control group thus represented a trial of the withdrawal of LABA and/or inhaled corticosteroid therapy, a question that is distinct from the proposed clinical question. The observed 40% dropout rate may well reflect this withdrawal of therapy, as clinical deterioration resulting from withdrawal of therapy has been demonstrated (2, 3), although spirometric variables did not clearly worsen in the study. We should not be surprised that sensitivity analysis seems to favor the addition of LABA or inhaled corticosteroids therapy to tiotropium, but the extent to which this is confounded by withdrawal effects is uncertain. Although not definitive, an analysis of patients not taking LABA or inhaled corticosteroids at baseline could perhaps give a sense of the sample size required to evaluate this effect. Although such a study would be expensive, the clinical question would probably be better answered by enrolling patients at the time that their treating physician would ordinarily consider additional therapy. Unfortunately, the current study was not designed to accurately assess the question posed.
and that withdrawal effects may have played a role in influencing clinical outcomes. However, the objective of our trial was to determine whether combination treatment with tiotropium plus salmeterol or tiotropium plus fluticasone-salmeterol improved clinical outcomes in adults with moderate and severe chronic obstructive pulmonary disease. We did not intend to limit the trial only to patients who were inhaled corticosteroid-naive and LABA-naive, because this would have potentially limited the generalizability of the study findings.
We agree that an interesting additional question would be to determine whether these combinations of medications are equally effective in inhaled corticosteroid-naive and LABA-naive patients. However, recruitment for this sort of study would probably have to occur in countries where use of long-acting bronchodilator medications is not already common practice for patients with moderate and severe chronic obstructive pulmonary disease. 
Shawn D. Aaron, MD

Chondroitin for Osteoarthritis of the Knee or Hip
TO THE EDITOR: Reichenbach and colleagues' meta-analysis on chondroitin for osteoarthritis of the knee or hip (1) is both timely and important. However, we are concerned that the authors' sweeping conclusions are not well grounded in their methodology.
Based on data extraction and synthesis, the overall effect size of chondroitin is large (see Reichenbach and colleagues' Figure 2 ; P Ͻ 0.001), although this conclusion is limited by the presence of heterogeneity among trials (I 2 ϭ 92%). Using meta-regression, the authors identified a subset of trials that provide homogeneity and stronger methodology, suggesting no effect on pain. The authors accurately state that a meta-regression analysis "should be viewed as hypothesis-generating" and is "observational in nature"-yet the results of the meta-regression form the cornerstone of the article's conclusion. But this conclusion makes no mention of the overall meta-analytic result or limitations, nor the limitations of the metaregression.
The prespecified "large trial" cutoff of 200 participants included 5 trials, with a summary small-to-moderate effect size of borderline significance. But the authors based their conclusions of "no effect" on only 3 of these trials (citing, in addition, reporting of intentionto-treat analyses), circumventing the most important benefit of systematic reviews that discourages a focus on a selective subset of studies. It is of great concern that the author's choice to base their conclusions on only these 3 studies was almost certainly made without being blinded to these studies' results (because the authors read all of the papers at the outset). Although, in the end, the conclusion that "use of chondroitin in routine clinical practice should therefore be discouraged" may eventually turn out to be true, it is not sufficiently supported by the authors' methodology. The data provided show that a meta-analysis demonstrates large effect size but is limited by heterogeneity between trials; meta-regression identifying the better trials suggests little or no effect, raising concerns about study quality; and these results apply to pain only and do not address disease progression, which also deserves further study (although the clinical significance of joint space narrowing is unknown) (2, 3) .
This important analysis needs to be added to the growing evidence on the effect of chondroitin for pain in osteoarthritis, 
TO THE EDITOR:
The recent meta-analysis on chondroitin sulfate by Reichenbach and colleagues (1) raises many issues related to clinical trials on osteoarthritis. The authors acknowledge that the studies reported in their review are highly heterogeneous in quality, which obviously imposes serious uncertainties to the accuracy of the conclusions drawn. This drawback plagues other meta-analyses in the same field.
With regard to the evaluation of the effect of chondroitin sulfate on osteoarthritis symptoms, the review brings up the issue of the great heterogeneity of the patient population included in the studies. Patient response to treatment is known to vary in relation to the severity of disease. Reichenbach and colleagues acknowledge that the inability to fully explore this dimension of the trials may have affected the findings and quality of the analysis. The recent study by Clegg and colleagues (2) elegantly demonstrated in osteoarthritis trials that the severity of symptoms could dramatically affect patient response to treatment with agents, such as chondroitin sulfate and glucosamine hydrochloride together (patients with more severe symptoms being more responsive). Of interest, these findings are somewhat contradictory to those of Reichenbach and colleagues' meta-analysis.
From a structural point of view and as suggested by the authors, attention should be given to most recent expert trials exploring the disease-modifying properties of chondroitin sulfate. Two of these long-term (2 years) studies (3, 4) were performed under optimal conditions and included more than 900 patients, including placebo control participants. In these trials, the primary outcomes were met, providing strong scientific evidence to support the disease-modifying effects of chondroitin sulfate.
As the quality of trials improves and important issues are addressed, it will become easier to draw firm conclusions on the therapeutic effectiveness of osteoarthritis drugs, including chondroitin sulfate. As outlined, the number of important limitations imposed on this meta-analysis and the fact that, as per the findings of the review, a clinically relevant effect of chondroitin sulfate in patients with lower-grade osteoarthritis cannot be excluded indicate that the jury is still out. With recent high-quality trials pointing toward a beneficial effect of chondroitin sulfate on osteoarthritis structures and symptoms alone or in combination treatment, the conclusions of Reichenbach and colleagues' review seem premature.
Jean-Pierre Pelletier, MD
University of Montreal, Osteoarthritis Research Unit, Notre-Dame Hospital, University of Montreal Hospital Centre Montreal, Quebec H2L 4M1, Canada
TO THE EDITOR:
In their meta-analysis of the literature on chondroitin for osteoarthritis of the knee or hip, Reichenbach and colleagues (1) correctly observed that their study is "limited by the quality of [the] included trials." They further disclosed that "several relevant variables were poorly reported" and that "most trials had poor methodological quality or inadequate reporting."
One critically important, poorly controlled relevant variable in the review (and in others involving therapeutic uses of dietary ingredients) deserves comment. As an expert who reviews analytical results for a variety of dietary ingredients and dietary supplements, I have found that the authenticity, potency, and purity of many dietary ingredients greatly vary. Simply put, raw-material quality is an underrecognized confounder in clinical trials. For example, on 11 April 2007, ConsumerLab.com reported that 73% of all products tested that contain chondroitin failed potency testing (2) . Between 1% and 8% of the labeled amount of chondroitin was found in 3 products, and none could be detected in a fourth product. Unfortunately, several different analytic tests are used commercially to measure the presence of chondroitin, some of which are more specific than others. Nonspecific analytic methods, such as size exclusion chromatography, provide unreliable results. Specific methods, such as enzymatic high-performance liquid chromatography, are far more appropriate. Agreement on analytic methods remains a challenge for this industry, and in my experience, most clinicians are simply not aware of this problem.
This raises the simple question: Did the products used in these studies contain therapeutic doses of chondroitin? If not, what conclusions can be drawn from these studies? And what are the implications for future research?
Michael D. Levin Health Business Strategies Clackamas, OR 97015
Potential Financial Conflicts of Interest: None disclosed.
IN RESPONSE:
As correctly pointed out by Dr. Goldberg and colleagues, our meta-analysis was hampered by the limited quality of included trials and the heterogeneity of their results. Therefore, the interpretation of the meta-analysis of all trials was difficult and the investigation of potential sources of heterogeneity mandatory (1) . The restriction of the analysis to large-scale, high-quality trials covering 40% of patients was not based on subjective judgment, but on results from stratified analyses and corresponding interaction tests. All explored factors were prespecified before initiating our systematic review. The 3 factors associated with treatment effects-concealment of allocation, intention-to-treat analysis, and sample size-are known to be associated with bias (2, 3). The cutoff of 200 patients used to explore the influence of trial size was specified in a grant proposal submitted to and funded by the Swiss National Research Programme 53 on musculoskeletal health (www.nfp53.ch/e_module .cfm?katiϭ6), which was initiated in 2004 before 4 of the 5 largescale trials became available. The only trial with more than 200 patients that was already available in 2004 (4) showed a large effect of chondroitin, which was incompatible with the effects found in any of the subsequent large-scale trials. It lacked adequate concealment of allocation, did not have a placebo control group, and failed to perform an intention-to-treat analysis.
It is joint pain that leads patients with osteoarthritis to seek medical help. We believe, therefore, that pain reduction should be the primary objective in osteoarthritis trials (5) . Contrary to Dr. Goldberg and colleagues' notion, we addressed radiographic joint space narrowing in a secondary analysis and found clinically irrelevant effects of chondroitin.
We agree with Dr. Pelletier that the STOPP (Study on Osteoarthritis Progression Prevention) trial (6) and the study by Michel and colleagues (7) met the primary end point in terms of joint space narrowing. However, the difference in mean changes of joint space narrowing in favor of chondroitin of 0.14 and 0.12 mm are evanes-cent, corresponding to an effect size of merely 0.1 SD. We disagree with Dr. Pelletier that Clegg and colleagues (8) provided robust evidence for an association between severity of symptoms and treatment response in patients receiving a combination of chondroitin and glucosamine. The results Dr. Pelletier refers to come from 1 of a multitude of subgroup analyses and might be explained by chance alone. As addressed in our discussion, there might be a role of chondroitin for patients with low-grade osteoarthritis, but this needs to be evaluated in large-scale trials performed independently from manufacturers.
We agree with Mr. Levin that pharmaceutical quality is important in evaluations of food supplements. However, the 3 large-scale, high-quality trials, which showed no effect, had either selected the investigational product on the basis of analyses of the capsules for purity, potency, and quality (8) or used an established preparation manufactured by the trial sponsor, which is approved and monitored by the Swiss drug approval agency (6, 7). 
CLINICAL OBSERVATION
Very Late Restenosis after Paclitaxel-Eluting Stent Implantation
Background: Late restenosis after drug-eluting stent implantation has been described for sirolimus-eluting stents (Cypher, Johnson & Johnson, Warren, New Jersey) (1-3) but not for paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, Massachusetts) (4) .
Objective: To describe a patient with a paclitaxel-eluting stent who presented with late in-stent restenosis 33 months after stent placement.
Case Report: A 76-year-old man with a history of an inferior myocardial infarction and coronary artery bypass grafting in 1989 presented to our center in April 2004 with stable angina pectoris. In 2001, he underwent bare-metal stent implantation in the saphenous vein graft to the right coronary artery, and a covered pericardium stent was placed in the vein graft because of disease progression in September 2003. In April 2004, a 3.5 ϫ 28 mm paclitaxel-eluting stent was implanted at 18 atmospheres under intravascular ultrasonography guidance in the vein graft for focal restenosis within the bare-metal stent ( Figure, A and B) . Routine follow-up angiography in November 2004 revealed a widely patent stent site in the vein graft (Figure, C) . In September 2005, a percutaneous intervention was performed on the proximal left anterior descending coronary artery. The stent site in the vein graft was widely patent, but there was a suggestion of distal disease progression (Figure, D) . In April 2006, another paclitaxel-eluting stent was implanted in the vein graft distal to the previously implanted stent (Figure, E) . In September 2006, follow-up angiography again revealed a widely patent stent site in the vein graft (Figure, F) . The patient presented with stable angina and a positive exercise test in January 2007. Angiography demonstrated focal restenosis of the vein graft in the proximal paclitaxeleluting stent, which was successfully treated by implantation of a 3.3 ϫ 23 mm sirolimus-eluting stent (Figure, G) .
Discussion: To our knowledge, this is the first published report of very late restenosis after paclitaxel-eluting stent implantation. Despite demonstration by angiography of patency up to 29 months after the procedure, late restenosis became clinically apparent at 33 months. In an animal model, paclitaxel-eluting stents showed lack of long-term neointimal suppression (5). The mechanism is unclear, but it may include inflammation (6, 7), disease progression within the stent (8) , and escape from inhibition and continued proliferation of some smooth-muscle cells (9) .
Conclusion: Restenosis occurred within a paclitaxel-eluting stent 33 months after implantation. This observation suggests the importance of long-term follow-up for patients receiving drug-eluting stents. 
